Edition:
United States

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

97.80EUR
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
€97.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,491
52-wk High
€124.90
52-wk Low
€55.86

Select another date:

Thu, Jul 19 2018

Photo

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

Select another date: